Ashrith Guha, MD
Advanced Heart Failure and Transplant Cardiology · Houston, TXNPI 1962609693
Payments from drug & device makers
Across 393 payments — averaging $1336.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$335K
- Endotronix, Inc.$115K
- Merck$33K
- Actelion Pharmaceuticals US, Inc.$22K
- Bayer$10K
- One Lambda, Inc.$5K
- plus $5K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 201 | $335,265 |
| Endotronix, Inc. | 5 | $115,147 |
| Merck | 15 | $33,475 |
| Actelion Pharmaceuticals US, Inc. | 36 | $21,844 |
| Bayer | 8 | $9,839 |
| One Lambda, Inc. | 7 | $5,024 |
| Cvrx, Inc. | 10 | $1,324 |
| Abiomed | 11 | $815 |
| Impulse Dynamics (USA) Inc. | 10 | $516 |
| Pfizer | 16 | $304 |
| Paragonix Technologies, Inc. | 1 | $261 |
| E.r. Squibb & Sons, L.L.C. | 16 | $256 |
| Alnylam Pharmaceuticals Inc. | 12 | $255 |
| Boehringer Ingelheim | 8 | $178 |
| Amgen | 10 | $152 |
| Novartis | 5 | $138 |
| Bridgebio Pharma, Inc. | 3 | $113 |
| Scpharmaceuticals Inc. | 4 | $85 |
| Lexicon Pharmaceuticals, Inc. | 2 | $47 |
| Madrigal Pharmaceuticals | 1 | $47 |
| AstraZeneca | 2 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| Tactile Systems Technology Inc | 2 | $26 |
| Astellas Pharma US Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Haemonetics Corporation | 1 | $24 |
| United Therapeutics Corporation | 1 | $20 |
| Sandoz | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Medtronic | 1 | $14 |
How this compares
$525,303 in reported general payments places this provider in the 85th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Houston
- Ajith NairHouston$1.3M
- Barry TrachtenbergHouston$352K
- Andrew CivitelloHouston$286K
- Arvind BhimarajHouston$269K
- Maria Patarroyo AponteHouston$166K
- Sriram NathanHouston$87K
- Rayan YousefzaiHouston$75K
- Cindy MartinHouston$67K
- Leo SimpsonHouston$30K
- Ju KimHouston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.